The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).

This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition that leads to vision impairment and is caused by mutations in the Rs1 gene. The development of this mouse model addresses a significant gap in the understanding of the biological mechanisms underlying XLRS, allowing researchers to explore gene and protein functions in a controlled environment. This model is crucial for testing potential therapeutic approaches aimed at restoring vision in affected individuals.

The RS-1 knockout mouse model provides a unique platform for biological studies, enabling researchers to investigate the effects of the Rs1 gene and its protein in vivo. This model is particularly valuable for pharmaceutical companies and academic institutions focused on developing treatments for retinal diseases. By utilizing this model, stakeholders can gain insights into disease progression and evaluate the efficacy of new therapeutic strategies, ultimately leading to advancements in patient care.

We are seeking licensing opportunities for this innovative technology, which has already been utilized in various laboratory studies. Collaborators and licensees will have the chance to leverage this model for their research and development efforts, contributing to the advancement of therapies for XLRS and related conditions. We welcome discussions on potential partnerships that can enhance the impact of this technology in the field of ophthalmology.